OBJECTIVE: The metabolic side effects of second-generation antipsychotics (SGA) are
serious and have not been compared head to head in a meta-analysis. We conducted a …

Objective To review recent advances in the epidemiology, pathobiology, and management
of weight gain and obesity in patients with schizophrenia and to evaluate the extent to which …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder,
have worse physical health and reduced life expectancy compared to the general …

Abstract Purpose of Review The prevalence of diabetes is 2–3-fold higher in people with
severe mental illness than the general population. There are concerns that antipsychotics …

Background The extent of metabolic and lipid changes in first-episode psychosis (FEP) is
unclear. Aims To investigate whether individuals with FEP and no or minimal antipsychotic …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Excess deaths from cardiovascular disease are a major contributor to the significant
reduction in life expectancy experienced by people with schizophrenia. Important risk factors …

Mental disorders are the greatest overall cause of disability. 1 Antipsychotic drugs (APDs)
are the most widely prescribed medications and are used frequently to control various …

Background: Antipsychotic-induced weight gain (AIWG) and other adverse metabolic effects
represent serious side effects faced by many patients with psychosis that can lead to …